ISO 14971 Risk Management Consulting for Medical Devices

The ISO 14971 risk management process typically includes planning, hazard identification, risk analysis, risk evaluation, risk control, evaluation of residual risk, benefit-risk assessment where needed, and ongoing production and post-production review. It is not a one-time exercise. For medical devices, the process must remain traceable across design, verification, clinical evidence, labeling, and post-market surveillance so regulators can see how safety decisions were made and maintained.

ISO 14971 is used to establish a structured process for identifying, evaluating, controlling, and monitoring risks associated with medical devices. Manufacturers use it to build risk management files, support regulatory submissions, justify safety-related design decisions, and maintain compliance throughout the device lifecycle. It is widely referenced in FDA, EU MDR, TGA, and other global regulatory contexts because it helps demonstrate a systematic approach to device safety.

In most cases, yes. While submission formats vary by market, regulators expect documented evidence that device risks were systematically identified, evaluated, and controlled. A complete risk management file often includes the plan, hazard analyses, risk evaluation criteria, control measures, verification of controls, residual risk conclusions, and links to labeling, clinical, and post-market evidence. Weak or fragmented files commonly trigger review questions and remediation work.

A typical ISO 14971 file includes a risk management plan, intended use and safety characteristics, hazard identification records, risk analyses such as FMEA or fault tree inputs, risk evaluation criteria, risk control measures, verification of implemented controls, residual risk assessments, benefit-risk conclusions where applicable, and production or post-production review inputs. Strong files also include traceability to design inputs, testing, labeling, clinical evidence, and complaint or PMS data.

Yes. Risk file remediation usually starts with a structured gap assessment against ISO 14971:2019 and the target regulatory pathway. From there, missing hazards, weak rationales, outdated controls, broken traceability, and unsupported residual risk conclusions are corrected in a prioritized sequence. The goal is not just to patch documents, but to create a coherent file that aligns with the current device design, evidence set, and regulatory expectations.

ISO 14971 supports both EU MDR and FDA expectations, but the file must be integrated properly. Under EU MDR, risk outputs should connect to GSPR conformity, clinical evaluation, PMS, and labeling. For FDA submissions such as 510(k), risk documentation should reinforce device safety, testing rationale, software documentation where relevant, and substantial equivalence arguments. The standard provides the framework, but regulators expect market-specific application and cross-referencing.

Risk management should be updated whenever there are meaningful changes to the device or new safety information becomes available. Common triggers include design changes, software updates, material changes, manufacturing changes, new verification data, complaint trends, adverse events, CAPAs, and post-market surveillance findings. Updating the file regularly helps maintain compliance and ensures the documented risk profile still reflects the device actually being marketed.

The timeline depends on the maturity of your documentation and the scope of support needed. A focused review or gap assessment may take a short engagement, while full file development or remediation across multiple products can take longer. Projects move faster when design records, testing evidence, labeling, and clinical inputs are organized. A structured consulting approach helps prioritize critical gaps first so submission or audit timelines stay realistic.